Leading experts have issued a stark warning that at-home gut health testing kits frequently deliver inaccurate and misleading results, highlighting an urgent need for greater regulation to ensure they are safe and effective for consumers. These direct-to-consumer kits, which typically cost between £100 and £400, claim to assess a wide range of conditions, from inflammatory bowel disease and irritable bowel syndrome to colorectal cancer, by analysing the gut microbiome.
Study Reveals Alarming Variability in Test Results
A new study published in the journal Communications Biology has exposed significant inconsistencies in the results produced by these popular kits. The research, led by Dr Scott Jackson, a molecular geneticist at the US National Institute of Standards and Technology, compared findings from 21 gut microbiome testing kits supplied by seven different companies. Using the same combined fecal sample from a single individual for each test, the team followed each company's specific collection instructions—whether involving whole bowel movements or used toilet paper—and sent samples back for analysis.
The results varied enormously, not only between different producers but even among identical kits from the same company. In one striking example, three identical samples analysed by kits from the same manufacturer yielded conflicting classifications: one was labelled 'unhealthy' while the other two were deemed 'healthy.' This inconsistency underscores the lack of standardised practices in the industry.
Systemic Issues in Microbiome Testing
Dr Jackson explained that bias can be introduced at every stage of the testing process, from sample collection and shipping methods to the sequencing technology and analytical techniques used. 'Even minor changes in methodology can lead to significant differences in results,' he noted. Currently, there are no universally accepted best practices for translating stool samples into a microbiome report, which contributes to the poor comparability plaguing the sector.
The study also highlighted specific discrepancies in bacterial detection. For instance, the American Gut Project, a well-established dataset, reports that the average person has a clostridium reading of just over 2.5 per cent. However, one company involved in the research reported five times this abundance, while three others failed to detect clostridium in one or more samples. Although clostridium includes pathogens like C. diff, which can cause diarrhoea, it typically resides harmlessly in the bowel.
Calls for Caution and Enhanced Regulation
In response to these findings, the study authors urge both consumers and healthcare professionals to exercise extreme caution when interpreting or acting on test results. Professor Jacques Ravel, a microbiology expert and co-author of the study, stated, 'I think it's almost impossible for any of these at-home tests to have clinical usefulness, which is a position a lot of scientists are sitting on.'
Dr Jackson emphasised that current regulations are insufficient to protect consumers, as test results may prompt individuals to make potentially unwarranted or unsafe lifestyle changes. He pointed out that many results are benchmarked against an average 'healthy' microbiome, yet defining a healthy microbiome remains challenging due to population heterogeneity, confounding factors, and the possibility of multiple healthy definitions.
Potential Harms and Consumer Risks
While most gut microbiome testing companies recommend healthier eating habits to restore balance—advice unlikely to cause direct harm—Dr Jackson warned that many consumers who purchase these tests suffer from chronic gut conditions. For these individuals, variability in test results or ineffective recommendations could lead to a loss of faith in the science and, more critically, delays in seeking appropriate medical care.
Additionally, some companies suggest that customers take expensive supplements, such as probiotics sold by the company itself, despite 'very little clinical evidence for efficacy,' according to the researchers. Although some firms share their workflows online, allowing consumers to see how their samples are processed, this transparency does not guarantee the validity or reliability of the results.
The study concludes that rigorous assessment has spotlighted systemic issues of poor comparability in the gut microbiome testing industry, underscoring the need for stricter oversight and clearer standards to safeguard public health.
